Delivery Order SPE2DB24D6038-SPE2DB25FEMPD
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $7,577.14 to AmerisourceBergen Drug Corp for the supply of CellCept 250 mg capsules (100 count) on August 13, 2025, with an ultimate completion date of August 14, 2025. This competitively awarded, firm fixed-price delivery order was issued without set-aside designation and will be performed at the contractor's facility in Conshohocken, Pennsylvania. CellCept (mycophenolate mofetil) is an immunosuppressant medication commonly...
- The Defense Logistics Agency awarded a delivery order valued at $12,986.33 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500 count) on August 11, 2025, with completion scheduled for August 12, 2025. This firm fixed price, competitively awarded delivery order represents a single pharmaceutical product shipment with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, is performing the...
- The Defense Logistics Agency awarded a delivery order valued at $12,027.50 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500-count) on August 7, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price contract involves no set-aside designation and specifies performance at the contractor's facility in Conshohocken, Pennsylvania. CellCept (mycophenolate mofetil) is an immunosuppressant medication used to prevent organ...
- The Defense Logistics Agency awarded a delivery order valued at $35,063.75 to AmerisourceBergen Drug Corp for 100 tablets of CellCept 500 mg, with an ultimate completion date of July 28, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is classified as a delivery order under a larger contract vehicle. The pharmaceutical product will be delivered to AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency awarded a delivery order valued at $33,203.38 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (500-count units). This competitive, firm fixed-price delivery order was executed on August 21, 2025, with an ultimate completion date of August 22, 2025. The contract does not carry a set-aside designation, indicating it was awarded through open competition. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in...
- The Defense Logistics Agency awarded a delivery order valued at approximately $27,938 to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (100-count units) on August 25, 2025, with completion targeted for August 26, 2025. This non-set-aside, competitively awarded delivery order reflects a firm fixed-price contract structure and will be performed at the vendor's facility in Conshohocken, Pennsylvania. CellCept (mycophenolate mofetil) is an immunosuppressant medication...
- This delivery order, awarded on August 13, 2025, by the Defense Logistics Agency to AmerisourceBergen Drug Corp, provides CellCept 250 mg capsules in quantities of 100 units at a ceiling value of $1,197.32. The contract utilizes firm fixed pricing and was competitively awarded without a set-aside designation. Performance will be executed from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen Drug Corp's...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of CellCept 500 mg tablets (500-count bottles) under a firm fixed-price contract with a ceiling value of $13,051.42. The delivery order, which is not set-aside, is scheduled for completion by July 31, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award represents a child contract under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of CellCept 500 mg tablets (100 count) on September 8, 2025, with an ultimate completion date of September 9, 2025. This competitively awarded, firm fixed-price delivery order has a ceiling value of $27,735.62 and carries no set-aside designation. The order will be fulfilled from the vendor's Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate headquarters as a...
- The Defense Logistics Agency awarded a delivery order valued at $2,545.90 to AmerisourceBergen Drug Corp for 100 tablets of CellCept 500 mg on September 3, 2025, with an ultimate completion date of September 4, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, fulfilled this order through its Corporate Office division as part of ongoing...
- SPE2DB24D6038Indefinite Delivery Contract
- SPE2DB24D6038-SPE2DB25FEMPDDelivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $13,296.81 to AmerisourceBergen Drug Corp for the supply of 100 capsules of CellCept 250 mg medication. This is a firm fixed-price, non-set-aside contract with an ultimate completion date of September 9, 2025, and represents a child order under AmerisourceBergen's larger pharmaceutical supply agreement with DLA. The pharmaceutical will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 through December 2026. The IDC serves as a comprehensive global pharmaceutical support vehicle enabling AmerisourceBergen to supply a broad range of medications and medical supplies to support military healthcare programs worldwide. CellCept (mycophenolate mofetil) is an immunosuppressant medication commonly used in military medical settings for transplant recipients and certain autoimmune conditions, consistent with AmerisourceBergen's demonstrated capability to fulfill federal medical procurement requirements through open competition across diverse therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.3k | 9/8/25 |